




Interactive Quarterly Performance Review (iQPR)

Strategic performance review



UFCW P E H W 4Q2020

A NOTE FROM SUMIT DUTTA, MD

We're pleased to present your fourth-quarter interactive Quarterly Performance Review (iQPR) results and reinforce our commitment to supporting your pharmacy benefit needs in 2021.

This year brings hope for new COVID-19 vaccines — which will be an important way to slow the spread of the virus. Helping our clients and members gain access to vaccines and related information is our top priority. In addition, we're strengthening our focus on affordability.

In this dynamic and fluid landscape, we're closely monitoring COVID-19 vaccine developments.

- As people around the world begin to get the COVID-19 vaccines, we'll keep you updated on clinical efficacy and safety data, manufacturing and distribution considerations, and state and federal coverage mandates.
- OptumRx® stands ready to support claims adjudication and reimbursement in alignment with plan sponsors, pharmacy partners and legislative guidelines.
- As details become available, OptumRx will provide our clients and members with educational information about how to access the vaccines.

While the race to develop vaccines and treatments for COVID-19 dominated headlines in 2020, the pandemic also intersected with many existing pharmacy trends in significant ways. Following are a few key highlights:

Accessibility


Technology became a cornerstone in delivering care safely during a pandemic. As patients and doctors worked to minimize person-to-person contact in 2020, adoption of video consultations with pharmacists and home delivery of medications rose sharply. In addition, home infusion treatments from Optum® Infusion Pharmacy reduced public exposure risk for patients who traditionally received infusion services in the hospital or other clinic settings.

Affordability

To help newly furloughed and unemployed workers losing vital health insurance afford their medication, we launched the Optum® Perks Prescription Relief Program. This program integrates into an employer's existing drug benefit plan to provide OptumRx members with ongoing savings and continued access to home delivery when their coverage ends.

We're grateful for your partnership and look forward to discussing your results with you. OptumRx will be here to help keep your organization safe and healthy.

Sincerely,




Sumit Dutta, MD
Chief Medical Officer
OptumRx

Summary of your plan

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019



Plan Paid PMPM

- UFCW P E H W 4Q2020's PMPM is trending at 17.0% versus previous period
- Rebates provided a 17.8% offset resulting in net plan paid of \$121.58 PMPM
- Diabetes, Inflammatory Conditions, and HIV disease states accounted for 36.1% of overall plan paid and increased \$5.54 PMPM in total plan paid. The benchmark increased \$4.92 PMPM in these categories



Your outcomes

- Clinical management programs have resulted in a total of \$111.10 PMPM plan savings



Your opportunities

- UFCW P E H W 4Q2020's top opportunity for savings is the UM Opportunity. This would result in total plan savings of \$7.66 PMPM, which represents 5.2% of total plan spend
- Projected \$31,388 total healthcare savings from programs

Total Savings: \$111.10 PMPM

Program savings

Concurrent Drug Utilization Review

Concurrent Drug Utilization Review (cDUR) is performed during the point of sale when members are filling their prescriptions. This includes the ongoing monitoring of drug therapy to drive positive patient outcomes. It presents dispensing pharmacists with the opportunity to alert prescribers or to resolve potential clinical concerns associated with the member's prescription.



Rebate Performance

Rebate offsets assist in reaching lowest net cost for prescription medications. Opportunities exist to improve rebates by adopting alternate OptumRx Formularies.



Member Experience

PreCheck MyScript

PreCheck MyScript simplifies the prescribing experience for members and physicians by providing real-time, member-specific medication pricing and coverage information as well as formulary-specific alternatives at the point of prescribing.



Outcomes Analysis Detail

UFCW P E H W 4Q2020

Total Savings: \$111.10 PMPM

Program name	PMPM savings	Total savings	Savings type	Utilizers	% savings out of total plan paid	Description
Concurrent Drug Utilization Review	\$84.75	\$538,151	Pharmacy	N/A	N/A	Concurrent Drug Utilization Review (cDUR) is performed during the point of sale when members are filling their prescriptions. This includes the ongoing monitoring of drug therapy to drive positive patient outcomes. It presents dispensing pharmacists with the opportunity to alert prescribers or to resolve potential clinical concerns associated with the member's prescription.
Rebate Performance	\$26.35	\$791,641	Pharmacy	N/A	17.8%	Rebate offsets assist in reaching lowest net cost for prescription medications. Opportunities exist to improve rebates by adopting alternate OptumRx Formularies.
PreCheck MyScript	N/A	\$243	Pharmacy	365	N/A	PreCheck MyScript simplifies the prescribing experience for members and physicians by providing real-time, member-specific medication pricing and coverage information as well as formulary-specific alternatives at the point of prescribing.
Retrospective Drug Utilization Review	N/A	\$0	Healthcare	0	N/A	OptumRx rDUR clinical offerings include safety management, gaps in care, star-focused and behavioral health. These programs focus on patient safety, improving quality of care and lowering total health care costs. By targeting clinical opportunities and guiding prescribing and therapy changes, we can help ensure better outcomes and healthier members.


Rebate Performance

UFCW P E H W 4Q2020

Outcomes date range: Jan - Dec 2020

Benchmark: LABOR AND TRUST

Current rebate value: \$26.35 PMPM



Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate.

UFCW P E H W 4Q2020's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of \$121.58, versus plan paid PMPM of \$147.93.

Net financial PMPM performance

	Drug cost	Member Paid	Plan Paid	Rebates	Net plan paid
Traditional	\$115.55	\$10.04	\$104.87	\$17.72	\$87.15
Specialty	\$44.28	\$1.21	\$43.06	\$8.63	\$34.43
Total	\$159.83	\$11.25	\$147.93	\$26.35	\$121.58

Total estimated rebate yield for reporting period: **\$791.6K**

Formulary compliance

Ensuring adherence to the formulary has a financial impact on the bottom line. The lower the percentage of Tier 3 prescriptions, the better the financial performance. Clients should strive for high generic use and formulary compliance. UFCW P E H W 4Q2020 is below the benchmark on use of Tier 3 drugs. Lowering Tier 3 drugs can help lower plan costs and potentially increase rebates.

TIER 3

3.3%

-3.7%
below benchmark



OptumRx offers alternate formularies and co-pay structure designed to drive higher formulary compliance.

Total savings: \$84.75 PMPM

Savings outcomes analysis summary



Concurrent Drug Utilization Review (cDUR) is performed during the point of sale when members are filling their prescriptions. This review involves the ongoing monitoring of drug therapy to ensure positive patient outcomes. It presents dispensing pharmacists with the opportunity to alert prescribers or to resolve potential clinical concerns associated with the member's prescription. Potential clinical opportunities include but are not limited to drug-drug interactions, duplicate therapy, over or under- utilization, and excessive or insufficient dosing. This type of review allows therapy for a patient to be altered, if necessary, to ensure safe and appropriate medication utilization. With OptumRx cDUR program, UFCW P E H W 4Q2020 has realized \$538,151 in total savings, with 70.4% of interventions that occurred out of 9,360 total claims.

Top 5 interventions

Sort Top 5 by: Number of interventions Total savings

Dosing/Duration

NUMBER OF INTERVENTIONS

4,144

TOTAL SAVINGS

\$448,902

% OF INTERVENTIONS

44.3%

Member is taking a medication for longer and/or at a higher dose than recommended.

Drug-Drug Interaction

NUMBER OF INTERVENTIONS

1,633

TOTAL SAVINGS

\$17,943

% OF INTERVENTIONS

17.4%

Member is taking 2 interacting medications and/or medication classes.

Duplicate Rx

NUMBER OF INTERVENTIONS

338

TOTAL SAVINGS

\$19,810

% OF INTERVENTIONS

3.6%

Member is taking 2 medications with the same ingredient.

Duplicate Therapy

NUMBER OF INTERVENTIONS

302

TOTAL SAVINGS

\$29,484

% OF INTERVENTIONS

3.2%

Member is taking 2 medications in the same drug class.

Morphine Equivalent Dose Limit Screening

NUMBER OF INTERVENTIONS

84

TOTAL SAVINGS

\$66

% OF INTERVENTIONS

0.9%

Member is taking opioids where the total cumulative daily dose exceeds the suggested morphine equivalent dose (MED).

All other

NUMBER OF INTERVENTIONS

33

TOTAL SAVINGS

\$2,993

% OF INTERVENTIONS

0.4%

PreCheck MyScript Program Outcomes

UFCW P E H W 4Q2020

Outcomes date range: Jan - Dec 2020

Total member savings: \$243

Average member savings per alternative switched: \$34.71

During this reporting period, PreCheck MyScript (PCMS) was used for 14.6% of your eligible members for a benefit check in their physician's office.

- PCMS was used by physicians to submit 4,050 trial claims for members
- 7 prescriptions were converted to Preferred Alternatives when PCMS was used



DID YOU KNOW?

Recent studies demonstrated that PreCheck MyScript technology is enabling improvement in affordability and health outcomes, including increase in medication adherence of up to 4% for selected chronic conditions.

Physicians utilization



-3.4% under benchmark


TOTAL PHYSICIANS

3,881

PHYSICIANS UTILIZING PCMS

498

Alternative conversions



+14.8% over benchmark

ALTERNATIVES OFFERED

42

ALTERNATIVES CONVERTED

7

Top 5 Preferred Alternatives converted representing 100.0% of all Preferred Alternative conversion activities

Preferred alternative	RXs	Transaction type
ALBUTEROL SULFATE HFA	2	Generic
AMOXICILLIN/CLAVULANATE POTASSIUM	2	Generic
METFORMIN HYDROCHLORIDE ER	2	Generic
AZELASTINE HCL	1	Generic

PreCheck MyScript Physician Details

UFCW P E H W 4Q2020

Outcomes date range: Jan - Dec 2020

Physicians utilizing PCMS:498

Top 10 physician specialties using PCMS tool for prescribing medications


Physician specialty	# of PCMS using physicians	% of Physician using PCMS	# of members served	# of trial claims submitted	% switch to alternatives	# of PA's submitted
Internal Medicine	60	13.3%	75	748	22.2%	0
Student in an Organized Health Care Education/Training Program/Student, Health Care	53	17.7%	40	480	9.1%	1
Physician Assistant	32	12.4%	33	289	33.3%	0
Family Practice	30	9.2%	32	256	66.7%	1
Nurse Practitioner, Family Health	26	12.8%	29	209	0.0%	0
Nurse Practitioner, Adult Health	5	15.6%	6	115	0.0%	0
Nurse Practitioner	12	7.4%	15	104	0.0%	0
Emergency Medicine	5	6.2%	6	82	0.0%	0
Hospitalist	7	28.0%	8	78	0.0%	0
Allopathic & Osteopathic Physicians Internal Medicine	9	9.6%	10	60	0.0%	0

Total opportunities: \$12.99 PMPM

Program savings


Utilization Management (UM)

The OptumRx UM programs ensure your members meet appropriate clinical criteria before initiation of certain drug therapy. This confirms your member's therapy is safe and consistent with accepted therapeutic guidelines; resulting in plan savings. UM may include Prior Authorization (PA), Quantity Limits (QL) and Step Therapy (ST).



Vigilant Drugs Opportunity

The OptumRx Vigilant Drug Program helps ensure clinically appropriate medications and minimize drug spend through targeted exclusion strategies that remove certain unnecessary medications from coverage.



Member Experience

Diabetes Management Opportunity

The OptumRx Diabetes Management program is a holistic solution designed to meet our clients' specific needs. By keeping members healthy we can help reduce complications and progression as well as curb medical visits and hospitalizations; leading to lower healthcare costs.



Opioid Opportunity

The Opioid Risk Management program is a comprehensive solution that uses advanced analytics and evidence-based clinical rules to decrease over prescribing, prevent opioid misuse, as well as identify and intervene with high-risk members.



Opportunity Analysis Detail

UFCW P E H W 4Q2020

Total opportunities: \$12.99 PMPM

Program name	PMPM savings	Total savings	Savings type	Utilizers	% savings out of total plan paid	Description
UM Opportunity	\$7.66	\$230,102	Pharmacy	705	5.2%	The OptumRx UM programs ensure your members meet appropriate clinical criteria before initiation of certain drug therapy. This confirms your member's therapy is safe and consistent with accepted therapeutic guidelines; resulting in plan savings. UM may include Prior Authorization (PA), Quantity Limits (QL) and Step Therapy (ST).
Vigilant Drugs Opportunity	\$5.34	\$160,304	Pharmacy	67	3.6%	The OptumRx Vigilant Drug Program helps ensure clinically appropriate medications and minimize drug spend through targeted exclusion strategies that remove certain unnecessary medications from coverage.
Diabetes Management Opportunity	N/A	N/A	N/A	317	N/A	The OptumRx Diabetes Management program is a holistic solution designed to meet our clients' specific needs. By keeping members healthy we can help reduce complications and progression as well as curb medical visits and hospitalizations; leading to lower healthcare costs.
Opioid Management Opportunity	N/A	N/A	N/A	172	N/A	The Opioid Risk Management program is a comprehensive solution that uses advanced analytics and evidence-based clinical rules to decrease over prescribing, prevent opioid misuse, as well as identify and intervene with high-risk members.
Adherence Opportunity Analysis	N/A	\$31,388	Healthcare	126	N/A	Medication non-adherence can lead to complications that require costly and potentially avoidable health care services. With the OptumRx Medication Adherence program, we identify and engage members to improve medication adherence and deliver improved health outcomes.

UM Opportunity Analysis

UFCW P E H W 4Q2020
Opportunities date range: Jan - Dec 2020

Estimated savings: \$7.66 PMPM


UM strategy by program

Utilization Management (UM) evaluates the application of prescribed medication therapy. Using evidence-based medicine, OptumRx UM promotes improvements in affordability, care quality, clinical consistency and patient safety. Based on analysis by OptumRx, its estimated that UFCW P E H W 4Q2020 can save \$7.66 PMPM by implementing our OptumRx Select Comprehensive UM program.




Prior Authorization	Quantity Limits	Step Therapy
UTILIZERS 465	UTILIZERS 82	UTILIZERS 158
PMPM SAVINGS \$5.41	PMPM SAVINGS \$0.47	PMPM SAVINGS \$1.78
PERCENT SAVINGS 70.6%	PERCENT SAVINGS 6.2%	PERCENT SAVINGS 23.2%

Top 5 therapy classes by: Prior Authorization Quantity Limits Step Therapy




Therapy class	Utilizers	Plan paid savings
Oncology	3	\$31,281
Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	3	\$22,180
Growth Hormones	1	\$11,884
Opioid Agonists & Combos	340	\$11,174
Chronic Inflammatory Disease	11	\$10,160

Top 5 therapy classes by: Prior Authorization Quantity Limits Step Therapy



Therapy class	Utilizers	Plan paid savings
Impotence Agents	19	\$2,924
Needles & Syringes	3	\$2,023
Postherpetic Neuralgia (PHN) Agents	1	\$1,904
Oral Anticoagulants	7	\$1,269
Insulin	1	\$1,261

Top 5 therapy classes by: Prior Authorization Quantity Limits Step Therapy



Therapy class	Utilizers	Plan paid savings
GLP-1 Receptor Agonists	23	\$13,049
Anaphylaxis Therapy Agents	2	\$12,379
DPP-4 Inhibitors & Combos	18	\$5,144
SGLT-2 Inhibitors & Combos	18	\$4,556
Insulin	14	\$3,894

Vigilant Opportunity Analysis

UFCW P E H W 4Q2020

Opportunities date range: Jan - Dec 2020


Projected cost avoidance: \$5.34 PMPM

Your opportunity

- OptumRx has several programs that help to effectively manage costs for higher cost drugs lacking additional value
- Currently, UFCW P E H W 4Q2020 spends \$3.04 PMPM on Clinical Duplicates for 23 utilizers


TOTAL UTILIZERS	TOTAL RXS	TOTAL PLAN PAID
67	204	\$160,304
3.5% of total	0.6% of total	3.6% of total

Clinical Duplicates




Excludes new medications with similar composition to existing medications with no significant clinical advantage.

High Cost Brands with Generics



Excludes certain higher-cost brand products when a clinically equivalent, lower-cost generic option is available.

High Cost Generics



Excludes specific higher-cost generic products without clinical advantage over other lower-cost generic therapeutic equivalents.

Non-FDA Approved Drugs



Excludes non-FDA approved products that are considered out of scope for review by the Optum Pharmacy and Therapeutics Committee.

Creams & Patches



Excludes topical products for the treatment of pain that are non-FDA approved or considered out of scope for review by the Optum Pharmacy and Therapeutics Committee.

Diabetes Opportunity Analysis

UFCW P E H W 4Q2020

Opportunities date range: Jan - Dec 2020

Total diabetic utilizers: 317


Diabetic utilizers



out of 1,875 utilizers

High risk diabetic utilizers have higher annualized plan paid than low risk diabetic utilizers : **\$3,872**


Average annual pharmacy plan paid



Pharmacy utilizers

5.8% of pharmacy utilizers filled a SGLT-2, GLP-1, or DPP-4.


Non-diabetics Low risk diabetics High risk diabetics



Pharmacy plan paid

39.4% of pharmacy plan paid attributed to diabetic members.

Non-diabetics Low risk diabetics High risk diabetics



Progression and Comorbidities

UFCW P E H W 4Q2020

Opportunities date range: Jan - Dec 2020


Total diabetic utilizers: 317

Diabetic member progression

Unclassified New diabetics Stable therapy Therapy change

6.6% new diabetic utilizers

Changing diabetic regimen is defined as either adding a DPP-4, GLP-1, or SGLT-2 where one was not previously used or discontinuing these medications.




Members with diabetes can quickly develop chronic comorbidities if lifestyle behaviors and changes aren't made. Comorbidities, like depression, hypertension, and hyperlipidemia can complicate and overwhelm diabetes care leading to an increase in overall healthcare costs. Our diabetes management program helps control the development and progression of comorbidities by getting ahead of conditions before they worsen, engaging with higher risk members sooner to better support self-care, appropriate therapy and improved adherence.

**Unclassified indicates data not available for prior period*

Diabetic member comorbidities



of total Diabetics



Pharmacy claims used as an indicator of disease. Drugs could be used for other purposes.

Adherence Opportunity Analysis

UFCW P E H W 4Q2020

Opportunities date range: Jan - Dec 2020

Total non-adherent utilizers: 126






By engaging members to improve medication adherence through medication consultations and prescriber collaboration, we can help improve members' adherence to their therapies.

- Projected total healthcare savings: \$31,388
- 19.9% of members are non-adherent to their medications

Sort by: Total healthcare savings

Adherence range: 0% – 40% 40% – 60% 60% – 80%



Opioid Utilization

UFCW P E H W 4Q2020

Opportunities date range: Sep - Dec 2020

Benchmark: LABOR AND TRUST

Utilizers: 172

5.2% of all Rx claims are filled for an Opioid

Opioid dependence can start in just a few days, and the risk of chronic opioid use increases with each additional day of opioid supplied, starting with the third day. Our Opioid Risk Management program, which includes point of sale, utilization management and retrospective drug utilization edits, are tightly aligned with CDC opioid prescribing guidelines which can help reduce exposure to excessive doses and prevent more members from transitioning from acute to chronic use.


- Opioid prescriptions account for 5.2% of all prescriptions this period, which is 2.1% higher than the benchmark
- 66 high opioid utilizers were identified this period, which is 9.4% higher than the benchmark

Opioid claims



PERCENT NON-COMPLIANT
5.1%

Opioid utilizers



HIGH UTILIZERS


38.4%

66 high utilizers

9.4% over benchmark

High utilizers – [view definition](#)

Claim breakdown



60.6% of all opioid Rxs were filled for short acting opioids. **36** Rxs were for medication assisted therapy (MAT) and **6** were for rescue therapy. CDC guidelines advise prescribers to manage pain with the lowest effective dose and to avoid or carefully justify doses for chronic users >90mg MME/day.

MAT – [view definition](#)

Overdose rescue therapy – [view definition](#)

MME – [view definition](#)

Utilizers by cumulative MED

6 utilizers exceed 180 MED/day

MED Scores	<90	90-179	180-240	>240
Utilizers	150	16	2	4

MED – [view definition](#)

Opioid Opportunity Assessment

UFCW P E H W 4Q2020


Opportunities date range: Sep - Dec 2020

Benchmark: LABOR AND TRUST

Percent non-compliant: 5.1%

Utilizers non-compliant to opioid Rx CDC guidelines

(new to therapy and chronic use)



[NTT - view definition](#) | [SAO - view definition](#) | [LAO - view definition](#) | [MME - view definition](#)



DID YOU KNOW?

0 opioid utilizing members use 3 or more pharmacies and 5 opioid utilizing members use 3 or more prescribers.

Identification, management and prevention of fraudulent or potential abuse of opioid medications are monitored and addressed by OptumRx through various means in pharmacy network audit capabilities and high touch clinical programs that include care coordination with opioid prescribers.

Opioid utilizers with potentially contraindicated medication use

SKELETAL MUSCLE
RELAXANTS

31

BENZODIAZEPINES

20

ANTICONSULSANTS

22

MEDICATION ASSISTED
THERAPY

N/A

PRENATAL

N/A

[Anticonvulsants - view definition](#)

Plan Performance

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total PMPM: \$147.93

Trend

Plan paid PMPM has increased 17.0% over the previous period driven primarily by utilization in traditional and cost for specialty.

Specialty represents 0.8% of claims.



+8.2% over benchmark




+17.6% over benchmark



-10.7% under benchmark

Plan Paid PMPM

Current period PMPM of \$147.93 equates to \$4.4M in pharmacy spend. 29.1% of the spend is attributed to specialty medications.



Adherence

Evidence based medicine guidelines promote the importance of the need to meet or exceed a clinical threshold for adherence based on Proportion of Days Covered (PDC).

The highly skilled pharmacists at Optum Specialty Pharmacy are well equipped to provide comprehensive therapy management for specialty conditions, which maximizes patient outcome.



Rebate impact

Rebate offsets add significant value in reaching lowest net cost for prescription medications. Opportunities exist to improve rebates by adopting alternate OptumRx Formularies.

Channel Management

Retail 90 ▲

PERCENTAGE OF RXs

35.7%

+20.7% over benchmark

Home delivery ▲

PERCENTAGE OF RXs

0.0%

-8.9% under benchmark

Optum Specialty Pharmacy ▲

PERCENTAGE OF SPECIALTY RXs

88.6%

+8.9% over benchmark

Over 95% of all non-specialty prescriptions are processed within the retail benefit as shorter than 30 day prescriptions. Opportunity exists to save money and improve adherence by shifting prescriptions to home delivery and retail 90.

Trend Components


UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019
Benchmark: LABOR AND TRUST

Total Traditional Specialty

Total trend: 17.0%


- UFCW P E H W 4Q2020's overall trend of 17.0% was 8.2% higher than benchmark
- Traditional spend influenced the trend contributing 86.7% (57.0% higher than benchmark)
- Specialty trend contributed 13.3% (57.0% lower than benchmark)



Total Traditional Specialty

Traditional trend: 21.6%


- Traditional trend contributed 86.7% to the overall trend (17.0%)
- Traditional accounts for 70.9% of overall total plan paid and was up from 68.2% in the prior period



Total Traditional Specialty

Specialty trend: 7.1%

- Specialty trend contributed 13.3% to the overall trend (17.0%)
- Specialty accounts for 29.1% of overall total plan paid and was up from 31.8% in the prior period



Disease States

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019
Benchmark: LABOR AND TRUST

Total Traditional Specialty

Total Plan Paid PMPM: \$147.93

Top 5 disease states account for 50% of total Plan Paid

- Diabetes accounts for 18.6% of total plan paid, with trend driven by Utilization. TRULICITY was the top drug
- Inflammatory Conditions accounts for 9.8% of total plan paid, with trend driven by Drug Mix. HUMIRA PEN was the top drug



Sort by: Plan Paid Contribution to trend

Diabetes ▲ PMPM \$27.55 +99.1% over benchmark Trend 25.2% Top driver: Utilization	Inflammatory Conditions ▼ PMPM \$14.52 +7.9% over benchmark Trend -8.2% Top driver: Drug Mix	HIV ▲ PMPM \$11.37 +144.2% over benchmark Trend 12.9% Top driver: Drug Mix
Asthma / COPD ▲ PMPM \$11.34 +114.0% over benchmark Trend 14.6% Top driver: Utilization	Endocrine And Metabolic ▲ PMPM \$9.42 +777.1% over benchmark Trend 90.4% Top driver: Cost	All other ▲ PMPM \$73.73 +73.3% over benchmark Trend 15.7%

Diabetes

According to industry literature, type 2 diabetes treatment accounts for 20% of healthcare spend. Advancements in diabetes treatment has led to more favorable outcomes, but at a higher treatment cost. Adherence to medications continues to be a challenge for most payers. This category contains multiple therapeutic classes, with different mechanisms of action. Members may be taking a single agent or multiple drug regimen to control diabetes. Rybelsus is a new non-insulin treatment that does not need to be injected, which offers a more convenient option for members with type 2 diabetes. Similar agents are slated to come on the market in the next few years, and offer more convenience (e.g. oral vs. injectable). These agents may increase medication adherence due to the convenience factor for patients.

Inflammatory Conditions

Trend has increased on average close to 20-30% year over year for the last several years. Most chronic inflammatory treatment is indicated for rheumatoid arthritis and psoriasis, but medications in this class have indications for over 20 different conditions. As the indication list continues to grow, increased utilization follows. Humira and Enbrel, are currently first and second in overall spending for all medications in the U.S, and new costly medications (e.g. Skirizi) continue to come on the market. Spend can be managed through utilization management and site of care steerage opportunities.

HIV

Numerous therapy options now exist for the treatment of HIV. Formulary management can help to manage spend in this category by promoting the lowest cost yet clinically sound alternatives. Several agents are approved for use of PrEP (pre-exposure prophylaxis), so utilization has increased in members who are at high risk but have not contracted the virus.

Asthma / COPD

Adequately treating asthma and COPD with medications is essential for active living. Treatment regimens vary by severity of the disease state, but most moderate cases are managed by using both controller medications, taken regularly to control the airways, and rescue medications (inhalers or nebulizer form) which are used when the condition is exacerbated. New products are continually marketed, as more drugs with different mechanisms of action are being developed. Some of the most utilized medications have recently become available in generic form, so we expect see a reduction in cost for the class.

Endocrine And Metabolic

Endocrine disorders are associated with an abnormality of one of the body's endocrine glands. This class primarily consists of generics, however possible new indications and new specialty medications in pipeline may add to the spend in this category.

Disease States

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Total Plan Paid PMPM: \$104.87


Top 5 disease states account for 61% of traditional Plan Paid

- Diabetes accounts for 26.3% of traditional plan paid with TRULICITY as the top drug
- HIV accounts for 10.8% of the traditional plan paid with BIKTARVY as the top drug




+120.9% over benchmark

Sort by: Plan Paid Contribution to trend




Generics drive lowest cost

● Brand ● Generic



- UFCW P E H W 4Q2020 generic dispensing rate (GDR) is -2.1% below benchmark
- Every 1% increase in GDR equates to a 4.6% reduction in traditional PMPM spend, or a \$5.59 PMPM savings

Home Delivery Opportunity



-26.8% under benchmark

- Shifting maintenance scripts to a 90 day supply at retail or home delivery can improve cost per script and promote higher adherence to chronic medications.

Disease States

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Total Plan Paid PMPM: \$43.06

Top 5 disease states account for 92% of specialty Plan Paid

- Inflammatory Conditions accounts for 32.5% of specialty plan paid with HUMIRA PEN as the top drug
- Endocrine And Metabolic accounts for 21.3% of specialty plan paid with SOMAVERT as the top drug




+67.6% over benchmark

Sort by: Plan Paid Contribution to trend

Inflammatory Conditions ▼ PMPM \$13.99 +8.3% over benchmark Trend -7.7% Top driver: Drug Mix	Endocrine And Metabolic ▲ PMPM \$9.16 +944.2% over benchmark Trend 90.8% Top driver: Utilization	Oncology ▼ PMPM \$7.33 +11.9% over benchmark Trend -15.4% Top driver: Utilization
Multiple Sclerosis ▲ PMPM \$6.73 +155.6% over benchmark Trend 46.7% Top driver: Drug Mix	Hepatitis ▼ PMPM \$2.57 +240.9% over benchmark Trend -2.7% Top driver: Drug Mix	All other ▼ PMPM \$3.27 -50.9% under benchmark Trend -24.4%


Orphan vs. Non-orphan

● Orphan ● Non-orphan



- Orphan drugs have been developed specifically to treat a rare medical condition
- These specialty medications can be extremely expensive, with an average ingredient cost over \$3K

New specialty drugs



TOTAL NEW DRUGS

43

NEW UTILIZERS

N/A

Disease States

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Total PMPM:\$147.93

Rank		Trend components												
Cu	Pv	Disease state	Utlzr	Total plan paid	GDR	Client utlizr per 1K	BOB utlizr per 1K	Curr PMPM	BOB PMPM	% Trend	Utlzn	Drug mix	Cost	Mbr contrb
1	1	Diabetes	329	\$827,687	51.2%	131.4	55.6	\$27.55	\$13.84	25.2%	14.6%	7.3%	4.1%	-0.8%
2	2	Inflammatory Conditions	28	\$436,147	40.6%	11.2	8.4	\$14.52	\$13.46	-8.2%	2.3%	-17.4%	7.6%	-0.6%
3	3	HIV	13	\$341,660	6.4%	5.2	2.7	\$11.37	\$4.66	12.9%	2.1%	5.5%	4.2%	1.1%
4	4	Asthma / COPD	293	\$340,745	45.4%	117.0	101.3	\$11.34	\$5.30	14.6%	20.2%	-6.4%	1.0%	-0.1%
5	7	Endocrine And Metabolic	16	\$282,970	74.0%	6.4	3.3	\$9.42	\$1.07	90.4%	46.3%	-14.5%	58.3%	0.4%
6	6	Cardiovascular	958	\$269,622	97.4%	382.6	192.1	\$8.97	\$2.67	28.0%	17.3%	7.2%	3.6%	-0.2%
7	5	Oncology	50	\$228,782	93.7%	20.0	9.3	\$7.61	\$6.67	-15.6%	18.5%	-28.4%	-5.5%	-0.1%
8	8	Blood Clot Prevention/Stroke Prevention	127	\$207,561	42.2%	50.7	24.1	\$6.91	\$3.28	50.2%	22.7%	14.9%	11.6%	0.9%
9	9	Multiple Sclerosis	2	\$202,333	0.0%	0.8	0.5	\$6.73	\$2.63	46.7%	-40.7%	143.9%	-57.9%	1.5%
10	10	Narcotic Analgesics	367	\$107,626	91.9%	146.6	90.9	\$3.58	\$0.91	0.3%	2.3%	-2.6%	-0.4%	1.1%
11	11	Cholesterol Lowering Agents	594	\$107,425	96.8%	237.2	121.7	\$3.58	\$1.45	5.4%	15.5%	-3.9%	-4.3%	-1.9%
12	13	Ulcer/Acid Reflux/Gerd	301	\$85,531	88.1%	120.2	83.7	\$2.85	\$0.64	13.8%	18.6%	-5.9%	0.9%	0.1%
13	12	Hepatitis	2	\$77,335	0.0%	0.8	0.5	\$2.57	\$0.76	-2.7%	20.2%	-20.5%	-4.0%	1.6%
14	14	Misc Skin Condition	320	\$74,737	93.1%	127.8	104.2	\$2.49	\$1.71	3.4%	20.2%	-11.7%	-5.7%	0.6%
15	15	Seizure Disorders	187	\$68,452	95.6%	74.7	51.5	\$2.28	\$1.26	-1.6%	17.7%	-17.9%	-0.3%	-1.0%
16	24	Non-Narcotic Analgesics	480	\$56,437	97.7%	191.7	156.1	\$1.88	\$0.40	129.3%	10.7%	85.6%	32.3%	0.7%
17	16	Ophthalmic Agents	139	\$48,970	70.1%	55.5	49.0	\$1.63	\$1.03	-4.9%	1.8%	-11.6%	4.8%	0.1%
18	17	Depression	291	\$45,295	97.1%	116.2	92.7	\$1.51	\$0.96	14.6%	12.0%	4.1%	-1.2%	-0.2%
19	27	Gastrointestinal, Misc	120	\$39,444	49.3%	47.9	37.9	\$1.31	\$1.23	84.3%	76.9%	-20.2%	25.3%	2.3%
20	19	Male And Female Hormone Replacement	58	\$39,146	65.4%	23.2	19.6	\$1.30	\$0.79	5.1%	12.0%	8.8%	-14.1%	-1.6%

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2021 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Disease States

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Total PMPM:\$104.87

Rank												Trend components				
Cu	Pv	Disease state	Utlzr	Total plan paid	GDR	Client utlzr per 1K	BOB utlzr per 1K	Curr PMPM	BOB PMPM	% Trend	Utlzn	Drug mix	Cost	Mbr contrb		
1	1	Diabetes	329	\$827,687	51.2%	131.4	55.6	\$27.55	\$13.84	25.2%	14.6%	7.3%	4.1%	-0.8%		
2	2	HIV	13	\$341,660	6.4%	5.2	2.7	\$11.37	\$4.66	12.9%	2.1%	5.4%	4.3%	1.1%		
3	3	Asthma / COPD	293	\$290,558	45.9%	117.0	101.2	\$9.67	\$4.85	22.0%	20.8%	-0.1%	1.2%	0.0%		
4	4	Cardiovascular	958	\$269,622	97.4%	382.6	192.0	\$8.97	\$2.60	28.0%	17.3%	7.2%	3.6%	-0.2%		
5	5	Blood Clot Prevention/Stroke Prevention	121	\$207,101	41.5%	48.3	23.4	\$6.89	\$3.25	50.4%	22.6%	15.3%	11.7%	0.9%		
6	6	Narcotic Analgesics	367	\$107,626	91.9%	146.6	90.9	\$3.58	\$0.90	0.3%	2.3%	-2.6%	-0.4%	1.1%		
7	7	Cholesterol Lowering Agents	594	\$107,425	96.8%	237.2	121.7	\$3.58	\$1.45	5.4%	15.5%	-3.9%	-4.3%	-1.9%		
8	8	Ulcer/Acid Reflux/Gerd	301	\$85,531	88.1%	120.2	83.7	\$2.85	\$0.64	13.8%	18.6%	-5.9%	0.9%	0.1%		
9	9	Misc Skin Condition	320	\$74,737	93.1%	127.8	104.2	\$2.49	\$1.71	3.4%	20.2%	-11.6%	-5.7%	0.6%		
10	10	Seizure Disorders	187	\$68,452	95.6%	74.7	51.5	\$2.28	\$1.08	-1.6%	17.7%	-17.9%	-0.4%	-1.0%		
11	18	Non-Narcotic Analgesics	480	\$56,437	97.7%	191.7	156.1	\$1.88	\$0.40	129.3%	10.7%	85.6%	32.3%	0.7%		
12	11	Ophthalmic Agents	139	\$48,970	70.1%	55.5	49.0	\$1.63	\$0.96	-4.9%	1.8%	-11.5%	4.8%	0.1%		
13	12	Depression	291	\$45,295	97.1%	116.2	92.7	\$1.51	\$0.95	14.6%	12.0%	4.1%	-1.2%	-0.2%		
14	21	Gastrointestinal, Misc	120	\$39,444	49.3%	47.9	37.9	\$1.31	\$1.06	84.3%	76.9%	-20.1%	25.2%	2.3%		
15	13	Male And Female Hormone Replacement	58	\$39,146	65.4%	23.2	19.6	\$1.30	\$0.76	5.1%	12.0%	8.8%	-14.1%	-1.6%		
16	23	Migraine/Pain Relief	30	\$37,694	69.9%	12.0	12.0	\$1.25	\$0.58	95.7%	42.9%	37.4%	17.3%	-1.8%		
17	14	Overactive Bladder / Incontinence	49	\$34,817	69.6%	19.6	7.2	\$1.16	\$0.40	-6.4%	20.5%	-22.9%	-3.4%	-0.5%		
18	20	Antibiotics	732	\$29,957	99.1%	292.4	258.5	\$1.00	\$0.63	30.7%	0.0%	60.6%	-17.7%	-12.1%		
19	19	Thyroid Replacement	197	\$29,937	82.7%	78.7	44.1	\$1.00	\$0.31	23.2%	16.5%	3.7%	2.5%	0.5%		
20	15	Contraception	95	\$28,943	88.5%	37.9	35.2	\$0.96	\$0.74	9.9%	-5.7%	9.8%	5.3%	0.5%		

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2021 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Disease States

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Total PMPM:\$43.06

Rank		Trend components												
Cu	Pv	Disease state	Utlzr	Total plan paid	GDR	Client utlizr per 1K	BOB utlizr per 1K	Curr PMPM	BOB PMPM	% Trend	Utlzn	Drug mix	Cost	Mbr contrb
1	1	Inflammatory Conditions	15	\$420,394	0.0%	6.0	3.8	\$13.99	\$12.92	-7.7%	0.5%	-16.1%	8.3%	-0.5%
2	3	Endocrine And Metabolic	2	\$275,141	5.9%	0.8	0.1	\$9.16	\$0.88	90.8%	60.7%	-23.1%	52.9%	0.4%
3	2	Oncology	4	\$220,271	0.0%	1.6	1.3	\$7.33	\$6.55	-15.4%	-9.6%	-6.3%	0.6%	-0.1%
4	4	Multiple Sclerosis	2	\$202,333	0.0%	0.8	0.5	\$6.73	\$2.63	46.7%	-40.7%	143.8%	-57.9%	1.5%
5	5	Hepatitis	2	\$77,335	0.0%	0.8	0.5	\$2.57	\$0.76	-2.7%	20.2%	-20.6%	-4.0%	1.6%
6	6	Asthma / COPD	2	\$50,187	0.0%	0.8	0.3	\$1.67	\$0.45	-15.2%	-32.1%	17.8%	-0.9%	-0.1%
7	7	Osteoporosis	4	\$23,014	0.0%	1.6	0.5	\$0.77	\$0.17	-31.0%	-14.1%	-20.4%	7.5%	-4.0%
8	8	Immunosuppressive Agents	5	\$10,766	100.0%	2.0	1.4	\$0.36	\$0.52	-31.6%	7.0%	-37.7%	1.2%	-2.0%
9	10	Osteoarthritis	9	\$7,487	0.0%	3.6	0.4	\$0.25	\$0.05	37.5%	20.8%	6.7%	12.9%	-2.9%
10	9	Pulmonary Hypertension	3	\$5,050	100.0%	1.2	0.6	\$0.17	\$0.86	-47.9%	24.5%	-58.6%	-14.9%	1.0%
11	15	Blood Cell Stimulators	1	\$896	0.0%	0.4	0.2	\$0.03	\$0.29	0.0%	0.0%	0.0%	0.0%	0.0%
12	12	Botulinum Toxn	1	\$518	0.0%	0.4	0.4	\$0.02	\$0.07	-77.6%	-66.3%	0.0%	-11.2%	0.0%
13	14	Blood Clot Prevention/Stroke Prevention	7	\$460	100.0%	2.8	1.1	\$0.02	\$0.03	-14.9%	127.2%	-63.6%	-81.4%	2.9%
14	N/A	Diagnostic Agents	2	\$0	0.0%	0.8	0.0	\$0.00	\$0.01	N/A	N/A	N/A	N/A	N/A
15	13	Drug Addiction	0	\$0	0.0%	0.0	0.1	\$0.00	\$0.03	-100.0%	-100.0%	0.0%	0.0%	0.0%
16	11	Enzyme Deficiency	0	\$0	0.0%	0.0	0.0	\$0.00	\$0.06	-100.0%	-100.0%	0.0%	0.0%	0.0%

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2021 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Top 20 Therapy Classes

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Rank		Trend components											
Cu	Pv	Therapy class	Disease state	Utilzr	Total plan paid	GDR	Curr PMPM	BOB PMPM	% Trend	Utilzn	Drug mix	Cost	Mbr contrb
1	1	Chronic Inflammatory Disease	Inflammatory Conditions	22	\$425,361	30.0%	\$14.16	\$12.97	-7.6%	13.4%	-25.4%	4.9%	-0.5%
2	2	Insulin	Diabetes	87	\$347,961	0.0%	\$11.58	\$4.71	20.8%	18.5%	2.9%	-0.7%	0.1%
3	3	HIV-Multiclass Combo	HIV	13	\$321,452	0.0%	\$10.70	\$4.11	13.4%	-0.6%	6.7%	6.2%	1.0%
4	4	Oncology	Oncology	46	\$228,508	93.5%	\$7.61	\$6.63	-15.2%	19.7%	-28.9%	-5.9%	-0.2%
5	6	Multiple Sclerosis	Multiple Sclerosis	2	\$202,333	0.0%	\$6.73	\$2.63	46.7%	-40.7%	143.9%	-57.9%	1.5%
6	9	GLP-1 Receptor Agonists	Diabetes	42	\$188,295	0.0%	\$6.27	\$3.54	55.8%	46.0%	-1.8%	12.5%	-0.9%
7	7	Inhaled Asthma/COPD Combo	Asthma / COPD	114	\$185,944	32.3%	\$6.19	\$2.86	48.8%	39.3%	6.1%	3.3%	0.1%
8	8	Oral Anticoagulants	Blood Clot Prevention/Stroke Prevention	72	\$182,995	15.5%	\$6.09	\$2.90	50.5%	26.7%	11.1%	11.8%	0.9%
9	11	Growth Hormones	Endocrine And Metabolic	1	\$179,348	0.0%	\$5.97	\$0.03	107.7%	59.1%	-30.8%	79.5%	-0.2%
10	5	DPP-4 Inhibitors & Combos	Diabetes	48	\$149,629	0.0%	\$4.98	\$2.74	5.8%	4.2%	0.1%	3.5%	-2.0%
11	10	SGLT-2 Inhibitors & Combos	Diabetes	39	\$121,475	0.0%	\$4.04	\$2.56	36.0%	30.6%	2.7%	4.3%	-1.7%
12	18	Endocrine Disorders	Endocrine And Metabolic	2	\$95,793	8.3%	\$3.19	\$0.08	65.7%	62.5%	-1.5%	3.3%	1.3%
13	12	Inhaled Bronchodilator	Asthma / COPD	224	\$76,572	36.6%	\$2.55	\$1.24	-9.9%	7.3%	-16.7%	-0.9%	0.4%
14	16	Proton Pump Inhibitors	Ulcer/Acid Reflux/Gerd	246	\$73,720	85.1%	\$2.45	\$0.52	15.5%	29.1%	-11.4%	-2.0%	-0.2%
15	13	Hepatitis C	Hepatitis	1	\$72,412	0.0%	\$2.41	\$0.56	-4.7%	1.0%	-7.4%	-0.2%	1.9%
16	15	Opioid Agonists & Combos	Narcotic Analgesics	357	\$68,798	91.4%	\$2.29	\$0.56	2.0%	1.7%	-6.4%	4.7%	2.0%
17	14	Anticonvulsants - 2nd Generation	Seizure Disorders	186	\$67,750	95.4%	\$2.25	\$1.21	-1.8%	18.6%	-18.6%	-0.8%	-1.0%
18	20	Angiotensin II Receptor Antagonists & Combos	Cardiovascular	348	\$67,223	98.0%	\$2.24	\$0.66	27.4%	15.8%	5.3%	6.6%	-0.3%
19	19	Statins & Combos	Cholesterol Lowering Agents	571	\$59,008	98.8%	\$1.96	\$0.66	2.2%	15.8%	-5.5%	-7.6%	-0.5%
20	32	Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	Non-Narcotic Analgesics	474	\$55,138	97.6%	\$1.84	\$0.36	146.1%	12.1%	99.9%	33.5%	0.7%

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2021 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Top 20 Therapy Classes

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Rank		Trend components												
Cu	Pv	Therapy class	Disease state	Utilzr	Total plan paid	GDR	Curr PMPM	BOB PMPM	% Trend	Utilzn	Drug mix	Cost	Mbr contrb	
1	1	Insulin	Diabetes	87	\$347,961	0.0%	\$11.58	\$4.71	20.8%	18.5%	2.9%	-0.7%	0.1%	
2	2	HIV-Multiclass Combo	HIV	13	\$321,452	0.0%	\$10.70	\$4.11	13.4%	-0.6%	6.7%	6.2%	1.0%	
3	6	GLP-1 Receptor Agonists	Diabetes	42	\$188,295	0.0%	\$6.27	\$3.54	55.8%	46.0%	-1.8%	12.5%	-0.9%	
4	4	Inhaled Asthma/COPD Combo	Asthma / COPD	114	\$185,944	32.3%	\$6.19	\$2.86	48.8%	39.3%	6.1%	3.3%	0.1%	
5	5	Oral Anticoagulants	Blood Clot Prevention/Stroke Prevention	72	\$182,995	15.5%	\$6.09	\$2.90	50.5%	26.7%	11.1%	11.8%	0.9%	
6	3	DPP-4 Inhibitors & Combos	Diabetes	48	\$149,629	0.0%	\$4.98	\$2.74	5.8%	4.2%	0.1%	3.5%	-2.0%	
7	7	SGLT-2 Inhibitors & Combos	Diabetes	39	\$121,475	0.0%	\$4.04	\$2.56	36.0%	30.6%	2.7%	4.3%	-1.7%	
8	8	Inhaled Bronchodilator	Asthma / COPD	224	\$76,572	36.6%	\$2.55	\$1.24	-9.9%	7.3%	-16.7%	-0.9%	0.4%	
9	11	Proton Pump Inhibitors	Ulcer/Acid Reflux/Gerd	246	\$73,720	85.1%	\$2.45	\$0.52	15.5%	29.1%	-11.4%	-2.0%	-0.2%	
10	10	Opioid Agonists & Combos	Narcotic Analgesics	357	\$68,798	91.4%	\$2.29	\$0.56	2.0%	1.7%	-6.5%	4.8%	2.0%	
11	9	Anticonvulsants - 2nd Generation	Seizure Disorders	186	\$67,750	95.4%	\$2.25	\$1.02	-1.8%	18.6%	-18.6%	-0.8%	-1.0%	
12	13	Angiotensin II Receptor Antagonists & Combos	Cardiovascular	348	\$67,223	98.0%	\$2.24	\$0.66	27.4%	15.8%	5.3%	6.6%	-0.3%	
13	12	Statins & Combos	Cholesterol Lowering Agents	571	\$59,008	98.8%	\$1.96	\$0.66	2.2%	15.8%	-5.5%	-7.6%	-0.5%	
14	24	Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	Non-Narcotic Analgesics	474	\$55,138	97.6%	\$1.84	\$0.36	146.1%	12.1%	99.9%	33.5%	0.7%	
15	17	Beta Blockers & Combos	Cardiovascular	259	\$54,545	94.2%	\$1.82	\$0.59	51.3%	15.0%	30.2%	5.6%	0.5%	
16	15	Antidepressants	Depression	291	\$45,295	97.1%	\$1.51	\$0.95	14.6%	12.0%	4.1%	-1.2%	-0.2%	
17	14	Opioid Partial Agonists	Narcotic Analgesics	13	\$38,828	98.3%	\$1.29	\$0.34	-2.5%	7.6%	0.9%	-10.5%	-0.5%	
18	29	Migraine Products	Migraine/Pain Relief	30	\$37,694	69.9%	\$1.25	\$0.58	95.7%	42.9%	37.4%	17.3%	-1.8%	
19	16	Urinary Antispasmodics & OAB Drugs	Overactive Bladder / Incontinence	49	\$34,817	69.6%	\$1.16	\$0.40	-6.4%	20.5%	-22.9%	-3.4%	-0.5%	
20	23	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	Cardiovascular	9	\$32,175	0.0%	\$1.07	\$0.37	38.1%	31.9%	1.6%	5.8%	-1.3%	

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2021 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Top 20 Therapy Classes

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Rank		Trend components											
Cu	Pv	Therapy class	Disease state	Utlzr	Total plan paid	GDR	Curr PMPM	BOB PMPM	% Trend	Utlzn	Drug mix	Cost	Mbr contrb
1	1	Chronic Inflammatory Disease	Inflammatory Conditions	15	\$420,394	0.0%	\$13.99	\$12.87	-7.7%	0.5%	-16.1%	8.3%	-0.5%
2	2	Oncology	Oncology	4	\$220,271	0.0%	\$7.33	\$6.54	-15.4%	-9.6%	-6.3%	0.6%	-0.1%
3	3	Multiple Sclerosis	Multiple Sclerosis	2	\$202,333	0.0%	\$6.73	\$2.63	46.7%	-40.7%	143.8%	-57.9%	1.5%
4	4	Growth Hormones	Endocrine And Metabolic	1	\$179,348	0.0%	\$5.97	\$0.03	107.7%	59.1%	-30.8%	79.5%	-0.2%
5	7	Endocrine Disorders	Endocrine And Metabolic	2	\$95,793	8.3%	\$3.19	\$0.06	65.7%	62.5%	-1.3%	3.2%	1.3%
6	5	Hepatitis C	Hepatitis	1	\$72,412	0.0%	\$2.41	\$0.56	-4.7%	1.0%	-7.4%	-0.2%	1.9%
7	6	Asthma	Asthma / COPD	2	\$50,187	0.0%	\$1.67	\$0.45	-15.2%	-32.1%	17.8%	-0.9%	-0.1%
8	8	Osteoporosis Agents	Osteoporosis	4	\$23,014	0.0%	\$0.77	\$0.17	-31.0%	-14.1%	-20.4%	7.5%	-4.0%
9	9	Transplant	Immunosuppressive Agents	5	\$10,766	100.0%	\$0.36	\$0.52	-31.6%	7.0%	-37.7%	1.2%	-2.0%
10	11	Osteoarthritis	Osteoarthritis	9	\$7,487	0.0%	\$0.25	\$0.05	37.5%	20.8%	6.7%	12.9%	-2.9%
11	10	Pulmonary Arterial Hypertension	Pulmonary Hypertension	3	\$5,050	100.0%	\$0.17	\$0.86	-47.9%	24.5%	-58.6%	-14.9%	1.0%
12	12	Hepatitis B	Hepatitis	1	\$4,922	0.0%	\$0.16	\$0.20	41.1%	34.6%	0.0%	6.5%	0.0%
13	17	Blood Modifier	Blood Cell Stimulators	1	\$896	0.0%	\$0.03	\$0.29	0.0%	0.0%	0.0%	0.0%	0.0%
14	14	Muscle Relaxants & Combos	Botulinum Toxn	1	\$518	0.0%	\$0.02	\$0.07	-77.6%	-66.3%	0.0%	-11.2%	0.0%
15	16	Injectable Anticoagulants	Blood Clot Prevention/Stroke Prevention	7	\$460	100.0%	\$0.02	\$0.03	-14.9%	127.2%	-63.6%	-81.4%	2.9%

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2021 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Top 20 Drug Names

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Rank												Trend components		
Cu	Pv	Drug name	Therapy class	Utilizr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr PMPM	Prev PMPM	BOB PMPM	% Trend	Top driver	% Top driver
1	5	BIKTARVY	HIV-Multiclass Combo	7	66	31.0	\$206,973	\$3,136	\$6.89	\$2.73	\$1.09	151.9%	Utilzn	134.8%
2	4	SOMAVERT	Growth Hormones	1	5	78.0	\$179,348	\$35,870	\$5.97	\$2.87	\$0.03	107.7%	Utilzn	59.1%
3	N/A	MAVENCLAD	Multiple Sclerosis	1	2	29.0	\$127,281	\$63,641	\$4.24	\$0.00	\$0.05	N/A	Cost	0.0%
4	N/A	ZYTIGA	Oncology	1	11	30.0	\$115,968	\$10,543	\$3.86	\$0.00	\$0.17	N/A	Cost	0.0%
5	6	ELIQUIS	Oral Anticoagulants	42	187	44.0	\$112,238	\$600	\$3.74	\$2.27	\$1.59	64.4%	Utilzn	52.6%
6	1	HUMIRA PEN	Chronic Inflammatory Disease	3	13	41.0	\$100,340	\$7,718	\$3.34	\$5.41	\$4.00	-38.2%	Utilzn	-41.9%
7	10	SOMATULINE DEPOT	Endocrine Disorders	1	11	28.0	\$95,353	\$8,668	\$3.17	\$1.92	\$0.03	64.9%	Utilzn	48.1%
8	N/A	POMALYST	Oncology	1	5	22.0	\$90,281	\$18,056	\$3.00	\$0.00	\$0.23	N/A	Cost	0.0%
9	N/A	COSENTYX SENSOREADY PEN	Chronic Inflammatory Disease	1	6	65.0	\$85,490	\$14,248	\$2.85	\$0.00	\$0.59	N/A	Cost	0.0%
10	11	COPAXONE	Multiple Sclerosis	1	13	28.0	\$75,051	\$5,773	\$2.50	\$1.86	\$0.23	34.6%	Utilzn	34.6%
11	14	TRULICITY	GLP-1 Receptor Agonists	15	86	36.0	\$74,353	\$865	\$2.47	\$1.73	\$1.38	42.8%	Utilzn	36.5%
12	N/A	EPCLUSA	Hepatitis C	1	3	28.0	\$72,412	\$24,137	\$2.41	\$0.00	\$0.28	N/A	Cost	0.0%
13	2	STELARA	Chronic Inflammatory Disease	1	3	56.0	\$66,956	\$22,319	\$2.23	\$5.28	\$1.60	-57.8%	Utilzn	-63.3%
14	13	DUPIXENT	Chronic Inflammatory Disease	4	21	27.0	\$63,863	\$3,041	\$2.13	\$1.77	\$0.72	20.0%	Utilzn	12.2%
15	8	JANUVIA	DPP-4 Inhibitors & Combos	22	81	62.0	\$62,964	\$777	\$2.10	\$2.08	\$1.38	0.6%	Cost	4.3%
16	9	LANTUS SOLOSTAR	Insulin	28	112	50.0	\$62,004	\$554	\$2.06	\$1.96	\$1.06	5.1%	Utilzn	15.7%
17	19	JARDIANCE	SGLT-2 Inhibitors & Combos	18	83	46.0	\$55,523	\$669	\$1.85	\$1.46	\$1.41	26.3%	Utilzn	24.2%
18	33	OTEZLA	Chronic Inflammatory Disease	2	16	30.0	\$55,481	\$3,468	\$1.85	\$0.87	\$0.68	112.9%	Utilzn	95.0%
19	29	FARXIGA	SGLT-2 Inhibitors & Combos	12	64	54.0	\$51,006	\$797	\$1.70	\$0.98	\$0.34	73.5%	Utilzn	69.3%
20	20	VICTOZA	GLP-1 Receptor Agonists	8	46	48.0	\$50,476	\$1,097	\$1.68	\$1.32	\$0.78	27.3%	Utilzn	20.6%

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2021 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Top 20 Drug Names

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Rank												Trend components		
Cu	Pv	Drug name	Therapy class	Utilzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr PMPM	Prev PMPM	BOB PMPM	% Trend	Top driver	% Top driver
1	1	BIKTARVY	HIV-Multiclass Combo	7	66	31.0	\$206,973	\$3,136	\$6.89	\$2.73	\$1.09	151.9%	Utilzn	134.8%
2	2	ELIQUIS	Oral Anticoagulants	42	187	44.0	\$112,238	\$600	\$3.74	\$2.27	\$1.59	64.4%	Utilzn	52.6%
3	5	TRULICITY	GLP-1 Receptor Agonists	15	86	36.0	\$74,353	\$865	\$2.47	\$1.73	\$1.38	42.8%	Utilzn	36.5%
4	3	JANUVIA	DPP-4 Inhibitors & Combos	22	81	62.0	\$62,964	\$777	\$2.10	\$2.08	\$1.38	0.6%	Cost	4.3%
5	4	LANTUS SOLOSTAR	Insulin	28	112	50.0	\$62,004	\$554	\$2.06	\$1.96	\$1.06	5.1%	Utilzn	15.7%
6	9	JARDIANCE	SGLT-2 Inhibitors & Combos	18	83	46.0	\$55,523	\$669	\$1.85	\$1.46	\$1.41	26.3%	Utilzn	24.2%
7	17	FARXIGA	SGLT-2 Inhibitors & Combos	12	64	54.0	\$51,006	\$797	\$1.70	\$0.98	\$0.34	73.5%	Utilzn	69.3%
8	10	VICTOZA	GLP-1 Receptor Agonists	8	46	48.0	\$50,476	\$1,097	\$1.68	\$1.32	\$0.78	27.3%	Utilzn	20.6%
9	7	TRESIBA FLEXTOUCH	Insulin	16	45	52.0	\$45,579	\$1,013	\$1.52	\$1.63	\$0.31	-6.7%	Cost	-5.1%
10	12	SYMTUZA	HIV-Multiclass Combo	1	12	30.0	\$44,438	\$3,703	\$1.48	\$1.12	\$0.12	32.6%	Utilzn	24.3%
11	15	XARELTO	Oral Anticoagulants	18	81	38.0	\$41,825	\$516	\$1.39	\$1.10	\$1.12	26.8%	Utilzn	21.3%
12	22	TOUJEO SOLOSTAR	Insulin	7	53	35.0	\$40,470	\$764	\$1.35	\$0.79	\$0.24	69.5%	Utilzn	87.8%
13	16	OXYCONTIN	Opioid Agonists & Combos	11	88	28.0	\$32,930	\$374	\$1.10	\$1.03	\$0.22	6.6%	Mbr Contrb	3.0%
14	23	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	9	58	38.0	\$32,175	\$555	\$1.07	\$0.78	\$0.37	38.1%	Utilzn	31.9%
15	21	BUPRENORPHINE HYDROCHLORIDE/ NALOXONE HYDROCHLORIDE	Opioid Partial Agonists	9	97	29.0	\$31,922	\$329	\$1.06	\$0.80	\$0.18	32.8%	Utilzn	39.9%
16	34	ANORO ELLIPTA	Inhaled Asthma/COPD Combo	11	62	44.0	\$31,596	\$510	\$1.05	\$0.58	\$0.18	81.3%	Utilzn	89.3%
17	64	TRELEGY ELLIPTA	Inhaled Asthma/COPD Combo	10	60	31.0	\$31,512	\$525	\$1.05	\$0.29	\$0.31	256.1%	Utilzn	233.9%
18	227	DUEXIS	Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	4	14	30.0	\$30,890	\$2,206	\$1.03	\$0.07	\$0.10	1,329.3%	Utilzn	1,156.6%
19	33	LEVEMIR FLEXTOUCH	Insulin	7	33	41.0	\$29,410	\$891	\$0.98	\$0.59	\$0.19	66.3%	Utilzn	75.5%
20	11	PREZCOBIX	HIV-Multiclass Combo	3	12	40.0	\$29,298	\$2,442	\$0.98	\$1.24	\$0.11	-21.1%	Utilzn	-23.1%

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2021 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Top 20 Drug Names

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Rank												Trend components		
Cu	Pv	Drug name	Therapy class	Utilzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr PMPM	Prev PMPM	BOB PMPM	% Trend	Top driver	% Top driver
1	4	SOMAVERT	Growth Hormones	1	5	78.0	\$179,348	\$35,870	\$5.97	\$2.87	\$0.03	107.7%	Utilzn	59.1%
2	N/A	MAVENCLAD	Multiple Sclerosis	1	2	29.0	\$127,281	\$63,641	\$4.24	\$0.00	\$0.05	N/A	Cost	0.0%
3	N/A	ZYTIGA	Oncology	1	11	30.0	\$115,968	\$10,543	\$3.86	\$0.00	\$0.17	N/A	Cost	0.0%
4	1	HUMIRA PEN	Chronic Inflammatory Disease	3	13	41.0	\$100,340	\$7,718	\$3.34	\$5.41	\$4.00	-38.2%	Utilzn	-41.9%
5	6	SOMATULINE DEPOT	Endocrine Disorders	1	11	28.0	\$95,353	\$8,668	\$3.17	\$1.92	\$0.03	64.9%	Utilzn	48.1%
6	N/A	POMALYST	Oncology	1	5	22.0	\$90,281	\$18,056	\$3.00	\$0.00	\$0.23	N/A	Cost	0.0%
7	N/A	COSENTYX SENSOREADY PEN	Chronic Inflammatory Disease	1	6	65.0	\$85,490	\$14,248	\$2.85	\$0.00	\$0.59	N/A	Cost	0.0%
8	7	COPAXONE	Multiple Sclerosis	1	13	28.0	\$75,051	\$5,773	\$2.50	\$1.86	\$0.23	34.6%	Utilzn	34.6%
9	N/A	EPCLUSA	Hepatitis C	1	3	28.0	\$72,412	\$24,137	\$2.41	\$0.00	\$0.28	N/A	Cost	0.0%
10	2	STELARA	Chronic Inflammatory Disease	1	3	56.0	\$66,956	\$22,319	\$2.23	\$5.28	\$1.60	-57.8%	Utilzn	-63.3%
11	9	DUPIXENT	Chronic Inflammatory Disease	4	21	27.0	\$63,863	\$3,041	\$2.13	\$1.77	\$0.72	20.0%	Utilzn	12.2%
12	15	OTEZLA	Chronic Inflammatory Disease	2	16	30.0	\$55,481	\$3,468	\$1.85	\$0.87	\$0.68	112.9%	Utilzn	95.0%
13	13	XELJANZ	Chronic Inflammatory Disease	1	10	30.0	\$43,935	\$4,394	\$1.46	\$0.92	\$0.24	58.5%	Utilzn	49.6%
14	12	NUCALA	Asthma	1	12	28.0	\$36,042	\$3,004	\$1.20	\$1.00	\$0.05	20.4%	Utilzn	15.4%
15	14	FORTEO	Osteoporosis Agents	1	6	28.0	\$19,609	\$3,268	\$0.65	\$0.88	\$0.10	-25.8%	Utilzn	-26.6%
16	17	FASENRA	Asthma	1	3	39.0	\$14,145	\$4,715	\$0.47	\$0.60	\$0.06	-21.6%	Utilzn	-30.3%
17	N/A	ALECENSA	Oncology	1	1	30.0	\$14,022	\$14,022	\$0.47	\$0.00	\$0.04	N/A	Cost	0.0%
18	37	SILDENAFIL CITRATE	Pulmonary Arterial Hypertension	3	7	32.0	\$5,050	\$721	\$0.17	\$0.04	\$0.10	333.6%	Cost	230.3%
19	30	VEMLIDY	Hepatitis B	1	3	50.0	\$4,922	\$1,641	\$0.16	\$0.12	\$0.16	41.1%	Utilzn	34.6%
20	29	MYCOPHENOLATE MOFETIL	Transplant	3	37	30.0	\$4,460	\$121	\$0.15	\$0.12	\$0.12	24.4%	Utilzn	24.5%

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2021 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Key Statistics

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Total Traditional Specialty

Plan paid PMPM:\$147.93

Client totals



The key metrics here help highlight the changes UFCW P E H W 4Q2020 has experienced period over period.

- Eligibility has decreased by -867.
- Number of utilizers has decreased by -383.

Total Rxs

CURRENT

31,718

PREVIOUS

39,922

PERCENT CHANGE

-20.6%

Total plan paid

CURRENT

\$4,444,545

PREVIOUS

\$5,115,057

PERCENT CHANGE

-13.1%

Utilizers

CURRENT

1,901

PREVIOUS

2,284

PERCENT CHANGE

-16.8%

Key statistics with benchmark comparison

Your benchmark comparison
LABOR AND TRUST

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 17.0%, compared to the benchmark trend of 8.8%
- Member Paid Share changed by 1.4% period over period, compared to the benchmark of -7.6%

Key statistics	Benchmark				
	Current	Previous	Percent change	Current	Percent change
Average age	50.0	47.6	4.9%	37.8	-1.0%
Plan paid PMPM	\$147.93	\$126.45	17.0%	\$80.86	8.8%
Plan paid per Rx	\$140.13	\$128.13	9.4%	\$119.12	11.6%
Rxs PMPM	1.06	0.99	7.0%	0.68	-2.5%
Average days supply	47.5	44.2	7.4%	40.2	5.6%
Days supply PMPM	50.1	43.6	14.9%	27.3	2.9%
Member paid share	7.0%	6.9%	1.4%	9.8%	-7.6%
Member paid per Rx	\$10.66	\$9.51	12.1%	\$12.91	2.3%
Generic dispensing rate	85.0%	84.2%	1.0%	87.1%	0.3%
Home delivery rate	0.0%	0.0%	0.0%	8.9%	4.0%
Retail 90 rate	35.7%	30.6%	16.7%	15.0%	16.7%
Percent of specialty plan paid	29.1%	31.8%	-8.5%	37.6%	8.3%

Key Statistics

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Total Traditional Specialty

Plan paid PMPM:\$104.87

Client totals



The key metrics here help highlight the changes UFCW P E H W 4Q2020 has experienced period over period.

- Eligibility has decreased by -867.
- Number of utilizers has decreased by -381.

Total Rxs

CURRENT

31,464

PREVIOUS

39,569

PERCENT CHANGE

-20.5%

Total plan paid

CURRENT

\$3,150,694

PREVIOUS

\$3,488,994

PERCENT CHANGE

-9.7%

Utilizers

CURRENT

1,900

PREVIOUS

2,281

PERCENT CHANGE

-16.7%

Key statistics with benchmark comparison

Your benchmark comparison
LABOR AND TRUST

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 21.6%, compared to the benchmark trend of 4.0%
- Member Paid Share changed by 2.4% period over period, compared to the benchmark of -5.6%

Key statistics				Benchmark	
	Current	Previous	Percent change	Current	Percent change
Average age	50.0	47.6	4.9%	37.8	-1.0%
Plan paid PMPM	\$104.87	\$86.25	21.6%	\$50.45	4.0%
Plan paid per Rx	\$100.14	\$88.18	13.6%	\$74.97	6.8%
Rxs PMPM	1.05	0.98	7.1%	0.67	-2.6%
Average days supply	47.6	44.3	7.5%	40.2	5.6%
Days supply PMPM	49.8	43.3	15.0%	27.1	2.9%
Member paid share	8.7%	8.5%	2.4%	12.9%	-5.6%
Member paid per Rx	\$9.58	\$8.26	16.0%	\$11.09	-0.1%
Generic dispensing rate	85.4%	84.7%	0.8%	87.5%	0.4%
Home delivery rate	0.0%	0.0%	0.0%	9.0%	4.1%
Retail 90 rate	35.9%	30.8%	16.6%	15.1%	16.8%

Key Statistics

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Total Traditional Specialty

Plan paid PMPM:\$43.06

Client totals



The key metrics here help highlight the changes UFCW P E H W 4Q2020 has experienced period over period.

- Eligibility has decreased by -867.
- Number of utilizers has decreased by -1.

Total Rxs

CURRENT

254

PREVIOUS

353

PERCENT CHANGE

-28%

Total plan paid

CURRENT

\$1,293,851

PREVIOUS

\$1,626,063

PERCENT CHANGE

-20.4%

Utilizers

CURRENT

58

PREVIOUS

59

PERCENT CHANGE

-1.7%

Key statistics with benchmark comparison

Your benchmark comparison
LABOR AND TRUST

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 7.1%, compared to the benchmark trend of 17.9%
- Member Paid Share changed by -12.9% period over period, compared to the benchmark of -1.3%

Key statistics				Benchmark	
	Current	Previous	Percent change	Current	Percent change
Average age	50.0	47.6	4.9%	37.8	-1.0%
Plan paid PMPM	\$43.06	\$40.20	7.1%	\$30.40	17.9%
Plan paid per Rx	\$5,093.90	\$4,606.41	10.6%	\$5,205.81	8.8%
Rxs PMPM	0.008	0.009	-11.1%	0.006	8.3%
Average days supply	32.8	32.5	0.9%	32.1	3.0%
Days supply PMPM	0.3	0.3	-2.1%	0.2	11.6%
Member paid share	2.7%	3.1%	-12.9%	4.1%	-1.3%
Member paid per Rx	\$143.28	\$149.41	-4.1%	\$222.40	7.3%
Generic dispensing rate	38.6%	36.0%	7.2%	30.2%	-6.6%
Home delivery rate	0.4%	0.0%	0.0%	1.4%	-6.5%
Retail 90 rate	6.3%	5.7%	10.5%	5.0%	17.9%

Specialty Dashboard

UFCW P E H W 4Q2020


Reporting date range: Jan - Dec 2020

Total specialty PMPM: \$43.06

Specialty pharmacy channels

This period, 88.9% of UFCW P E H W 4Q2020's specialty scripts were managed through Optum, representing:

- \$1,207,209 total Optum Specialty Pharmacy plan paid
- 225 specialty scripts managed across Optum's channels
- 225 or 100.0% of specialty scripts filled through Optum Specialty Pharmacy



OPTUM

Optum Specialty Pharmacy

RXS
225


PERCENTAGE
100.0%

Optum Infusion Pharmacy

RXS
N/A


PERCENTAGE
N/A

Specialty adherence



Evidenced based medicine guidelines promote the importance of the need to meet or exceed a clinical threshold for adherence based on Proportion of Days covered (PDC). The highly skilled pharmacists at Optum are well equipped to provide comprehensive therapy management for specialty conditions, which maximizes patient outcome.

Optum Specialty Pharmacy engagement



Optum Specialty Pharmacy recognizes each patient has different experiences and different needs, thus we approach clinical management using a therapy solutions model. This program provides a seamless experience for our patients creating a continuum of care between prescribers, clinical, and home.

Copay assistance



Manufacturer copay assistance can be an asset to both members and clients because it helps offset the financial burden to your members which can have the additional benefit of better medication adherence and dedication to treatment.

High cost utilizers



The population of high cost utilizers is an important population sub-group that needs to be monitored and catered with a more focused clinical care. Optum has a wide range of available programs that supports these members and manage their conditions.

Traditional Adherence

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Oct 2019 - Sep 2020

Total Traditional Specialty

Average adherence: 89.8%

Our adherence program offers a continuum of care and full service capabilities. Leveraging advanced analytics, the program focuses on higher risk members, monitors behaviors for improved adherence, offers expert consultations and engages individuals through preferred channel of communications. By tracking patients' PDC (Proportion of Days Covered) for select traditional classes, the average adherence for UFCW P E H W 4Q2020 targeted patients is 89.8%.



Traditional adherence measured by adherence class

Sort top 5 by: Utilizers Average adherence

Hypertension AVG ADHERENCE 92.6% +0.2% from previous UTILIZERS 547	Statins AVG ADHERENCE 89.9% -0.4% from previous UTILIZERS 321	Diabetes AVG ADHERENCE 91.5% +1.1% from previous UTILIZERS 162
Depression AVG ADHERENCE 86.0% -1.7% from previous UTILIZERS 142	Respiratory Conditions AVG ADHERENCE 82.9% -1.3% from previous UTILIZERS 73	All other AVG ADHERENCE 85.7% -0.1% from previous UTILIZERS 151

Specialty Adherence

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Oct 2019 - Sep 2020

Total Traditional Specialty

Average adherence: 89.3%

Medication adherence is an important component of an appropriate medication management program. The highly skilled pharmacists at Optum Specialty Pharmacy are well equipped to provide comprehensive therapy management for specialty conditions to maximize patient outcomes. By tracking patients' PDC (Proportion of Days Covered) for select specialty classes, the average adherence for UFCW P E H W 4Q2020 targeted patients is:

- 89.3% overall average adherence
- 7.3% higher than the previous reporting period



Specialty adherence by adherence class

Sort top 5 by: Utilizers Average Adherence

Inflammatory Conditions AVG ADHERENCE 79.9% +3.1% from previous UTILIZERS 5	Transplant AVG ADHERENCE 99.8% +2.5% from previous UTILIZERS 3	Multiple Sclerosis AVG ADHERENCE 96.8% -2.9% from previous UTILIZERS 1
Oncology AVG ADHERENCE 97.6% +29.0% from previous UTILIZERS 1	 AVG ADHERENCE N/A from previous UTILIZERS	

Hepatitis C persistency

Hep C is a condition that requires a shorter medication regimen compared to other specialty adherence classes, to capture member's medication compliance OptumRx offers reporting on Hep C persistency and adherence based on gap days.

Specialty High Cost Utilizers

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019


Total high cost utilizers: 1

2.1% of utilizers have an average plan paid per month that exceeds \$16,500

The population of high cost utilizers is an important population sub-group that needs to be monitored and catered with a more focused clinical care. Optum Specialty Pharmacy has a wide range of available programs that supports these members and manage their conditions. This period, UFCW P E H W 4Q2020's high cost population represents:

- 1 high cost utilizers out of 47 total specialty utilizers
- \$0.3M or 21.1% of total specialty spend was driven by the high cost utilizers

High cost utilization breakdown



Top 5 high cost specialty disease states

Sort top 5 by: High cost total spend High cost % of spend High cost utilizers

Disease state	High cost total spend	High cost % of spend	High cost utilizers	Rxs	Avg plan paid per month
Endocrine And Metabolic	\$274,700	99.8%	1	16	\$22,891.71

New Pipeline Drug: Aducanumab

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020

Drug review Traditional Specialty Generics

Projected Year 1 ingredient cost PMPM: \$0.00

Alzheimer's disease is the most common cause of dementia among older adults with an estimated 5.7 million Americans living with the disease in 2018.

Aducanumab is a novel monoclonal antibody that reduces amyloid plaques in the brain. While the clinical trial efficacy was mixed and there is uncertainty on its approval, aducanumab would potentially be the first disease modifying therapy for Alzheimer's. There is a high unmet need for treatments since Alzheimer's is a leading cause of morbidity and mortality among the elderly and there is a lack of treatment options that have shown benefit in reducing or slowing cognitive decline. Existing therapies (eg, Aricept) are also considered symptomatic therapies that do not change the underlying pathophysiology of the disease.

PRIMARY INDICATION

Alzheimer's disease

MANUFACTURER

Biogen

ROUTE OF ADMINISTRATION

IV

CURRENTLY APPROVED TREATMENT (OTHER)

Aricept, Razadyne ER, Exelon, Namenda

EXPECTED APPROVAL DATE

3/7/2021

PRELIMINARY ORX STRATEGY

PA

PROJECTED UTILIZERS

YEAR 1

0

YEAR 2

0

YEAR 3

0

INGREDIENT COST PMPM

\$0.00

\$0.00

\$0.00

Year 1

Year 2

Year 3



According to our estimates, cancer will account for the largest therapeutic area in the pipeline, followed by neurology, infectious diseases, and endocrine. Rare diseases will continue to be a central focus of drug development; Approximately 30 - 40% of pipeline drugs that could reach the market in 2020 will have orphan designations for small targeted populations.

Selected Pipeline Drugs

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020

Drug review **Traditional** Specialty Generics

Projected Year 1 ingredient cost PMPM:\$0.33

Drug name	Indication	Route of admin	Approval date	Projected utilizers	Projected PMPM ing cost
Viaskin Peanut	Peanut Allergy	Transdermal	2022	1	\$0.21
Obeticholic acid	Nonalcoholic steatohepatitis	Oral	2022	0	\$0.12

Selected Pipeline Drugs

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020

Drug review Traditional **Specialty** Generics

Projected Year 1 ingredient cost PMPM:\$0.70

Drug name	Indication	Route of admin	Approval date	Projected utilizers	Projected PMPM ing cost
Roctavian (valoctocogene roxaparvovec)	Hemophilia A	Intravenous	Mid-2022	0	\$0.65
Tenazumab	Osteoarthritis	Subcutaneous	2Q 2021	0	\$0.04
Roxadustat	Chronic kidney disease-anemia	Oral	3/20/2021	0	\$0.01
Aducanumab	Alzheimer's disease	Intravenous	3/7/2021	0	\$0.00

Selected Pipeline Drugs

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020

Drug review Traditional Specialty **Generics**

Projected Year 1 ingredient cost PMPM:\$0.50


Brand drug name	Generic drug name	Expected launch date	Utilizers	Brand Drug Ing Cost	Projected Annual Ing Cost Saving
Absorica	isotretinoin	02/01/2021	1	\$4,204	\$2,521
Northera	droxidopa	02/18/2021	0	\$0	\$0
Chantix	varenicline	04/01/2021	12	\$9,380	\$6,488
Forteo	teriparatide	04/01/2021	1	\$21,202	\$12,421
Velphoro	sucroferric oxyhydroxide	04/01/2021	1	\$15,743	\$9,365
Pomalyst	pomalidomide	05/01/2021	1	\$90,283	\$62,595
Perforomist	formoterol fumarate	06/22/2021	0	\$0	\$0
Daliresp	roflumilast	07/01/2021	0	\$0	\$0
Dexilant	dexlansoprazole	07/01/2021	19	\$27,799	\$16,214
Restasis	cyclosporine	07/01/2021	6	\$10,106	\$5,641
Toviaz	fesoterodine	07/01/2021	1	\$0	\$0

Optum Specialty Pharmacy Initial Clinical Consultation Participation

UFCW P E H W 4Q2020

Reporting date range: Jan - Dec 2020 vs Jan - Dec 2019

Total consults completed: 3



6 total eligible utilizers

UFCW P E H W 4Q2020's utilizers who are filling a first fill eligible medication for the first time are provided with a baseline drug and disease consultation, as well as an assessment with an Optum Specialty Pharmacy clinician at the time of fill. Because we believe this is a key element of specialty patient care, all utilizers are enrolled in the program unless they choose to opt-out. This period, UFCW P E H W 4Q2020's program participation metrics are:

- 6 eligible utilizers with completed first fill consultations
- Hepatitis C has the highest participation rate
- Inflammatory Conditions has the lowest participation rate

Participation by therapy class

Sort by: Eligible utilizers Percentage of complete consults

Therapy class	Eligible utilizers	Completed consults	Completion rate	Active opt-out	Passive opt-out	In-progress
Oncology	2	1	50.0%	0.0%	0.0%	50.0%
Hepatitis C	1	1	100.0%	0.0%	0.0%	0.0%
HIV	1	0	0.0%	0.0%	0.0%	100.0%
Inflammatory Conditions	1	0	0.0%	0.0%	0.0%	100.0%
Multiple Sclerosis	1	1	100.0%	0.0%	0.0%	0.0%

Report parameters

CLIENT REPORT NAME
UFCW P E H W 4Q2020

SAVE-AS NAME
UFCW P E H W 4Q2020

DATE BASIS
Submit Date

DATE RANGE
Jan - Dec 2020 vs Jan - Dec 2019

COST BASIS
Plan Paid

REPORT RUN DATE
01/24/2021

MEMBER BASIS
PMPM

REQUEST ID
UFCWUPE-1242021-14320

BENCHMARK
LABOR AND TRUST
101 clients
1,354,753 average member count

OPPORTUNITY ANALYSIS PROGRAM EXCLUSION
Formulary Analysis

OUTCOMES ANALYSIS PROGRAM EXCLUSION
UM Outcomes, Vigilant Outcomes

CARRIER ID
UFCWUPE

ACCOUNT ID
*ALL

GROUP ID
*ALL

About OptumRx

OptumRx is a pharmacy care services company helping clients and approximately 59 million members achieve better health outcomes and lower overall costs through innovative prescription drug benefits services, including network claims processing, clinical programs, formulary management, specialty pharmacy care and infusion services. OptumRx is part of Optum®, a leading information and technology-enabled health services business dedicated to making the health system work better for everyone.

To learn more about iQPR, contact your OptumRx representative or send an email to optumrx@optum.com.



2300 Main Street, Irvine, CA 92614

All Optum trademarks and logos are owned by Optum, Inc. All other trademarks are the property of their respective owners.

© 2021 Optum, Inc. All rights reserved. ORX1280143_201210